Acute respiratory distress syndrome (ARDS) is one of the critical stages of COVID-19, leading to lung injury and hemolysis. Dysfunctional hemoglobin (Hb) suffers low-level oxygenation, overloaded iron, and down-regulation of hemeoxygenase-1 (HO-1), representing potential therapeutic interventions. This Viewpoint outlines the Hb–HO-1 system as a host-cell target, and proposes possible therapies, including iron chelation and CO therapies, against COVID-19 with ARDS.

中文翻译：

---

Heme/Hemeoxygenase-1 系统是 COVID-19 严重并发症患者的潜在治疗干预措施

急性呼吸窘迫综合征 (ARDS) 是 COVID-19 的关键阶段之一，可导致肺损伤和溶血。功能失调的血红蛋白 (Hb) 遭受低水平氧合、铁过载和 hemeoxygenase-1 (HO-1) 下调，代表潜在的治疗干预。该观点概述了 Hb-HO-1 系统作为宿主细胞靶点，并提出了针对具有 ARDS 的 COVID-19 的可能疗法，包括铁螯合和 CO 疗法。